HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Abstract
A retrospective study was performed to collect information regarding efficacy and toxicity of cidofovir (CDV) in allogeneic stem cell transplant patients. Data were available on 82 patients. The indications for therapy were cytomegalovirus (CMV) disease in 20 patients, primary preemptive therapy in 24 patients, and secondary preemptive therapy in 38 patients. Of the patients, 47 had received previous antiviral therapy with ganciclovir, foscarnet, or both drugs. The dosage of CDV was 1 to 5 mg/kg per week followed by maintenance every other week in some patients. The duration of therapy ranged from 1 to 134 days (median, 22 days). All patients received probenecid and prehydration. Ten of 20 (50%) patients who were treated for CMV disease (9 of 16 with pneumonia) responded to CDV therapy, as did 25 of 38 (66%) patients who had failed or relapsed after previous preemptive therapy and 15 of 24 (62%) patients in whom CDV was used as the primary preemptive therapy. Of the patients, 21 (25.6%) developed renal toxicity that remained after cessation of therapy in 12 patients. Fifteen patients developed other toxicities that were potentially due to CDV or the concomitantly given probenecid. No toxicity was seen in 45 (61.6%) patients. Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy. However, additional studies are needed before CDV can be recommended for preemptive therapy.
AuthorsP Ljungman, G L Deliliers, U Platzbecker, S Matthes-Martin, A Bacigalupo, H Einsele, J Ullmann, M Musso, R Trenschel, P Ribaud, M Bornhäuser, S Cesaro, B Crooks, A Dekker, N Gratecos, T Klingebiel, E Tagliaferri, A J Ullmann, P Wacker, C Cordonnier
JournalBlood (Blood) Vol. 97 Issue 2 Pg. 388-92 (Jan 15 2001) ISSN: 0006-4971 [Print] United States
PMID11154213 (Publication Type: Journal Article)
Chemical References
  • Antiviral Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • Cytosine
  • Cidofovir
Topics
  • Adolescent
  • Adult
  • Antiviral Agents (administration & dosage, standards, toxicity)
  • Child
  • Child, Preschool
  • Cidofovir
  • Cytomegalovirus Infections (drug therapy, etiology, prevention & control)
  • Cytosine (administration & dosage, analogs & derivatives, standards, toxicity)
  • Data Collection
  • Drug Evaluation
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Organophosphonates
  • Organophosphorus Compounds (administration & dosage, standards, toxicity)
  • Renal Insufficiency (chemically induced, virology)
  • Retrospective Studies
  • Survival Rate
  • Transplantation, Homologous (adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: